Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment.
Thomas SE, Seyger MMB, Mangnus JE, Otero ME, Gostynski AH, Njoo MD, Ossenkoppele PM, Haeck IM, Hendricksen-Roelofzen JHJ, Körver JEM, Dodemont SRP, Tupker RA, Berends MAM, Weppner-Parren LMJT, Keijsers RRMC, Oostveen AM, Peters B, Mommers R, van Doorn MBA, Tjioe M, Veldkamp WR, Kuijpers ALA, Kleinpenning MM, de Jong EMGJ, van den Reek JMPA.
Thomas SE, et al.
Am J Clin Dermatol. 2024 May 27. doi: 10.1007/s40257-024-00868-x. Online ahead of print.
Am J Clin Dermatol. 2024.
PMID: 38802618
No abstract available.